Market Trends of Cell Analysis Instruments Industry
The Cell Counting Segment is Expected to Register a Significant Growth During the Forecast Period
Cell counting is done to compare different cell populations or responses. It is fundamental and critical to numerous biological experiments. Cell counting is done by various methods, such as automated cell counters, cell cycle analysis, and counting cells without cell staining. Cell counting is used in medicine to understand the concentration of blood cells, which can provide crucial information about the health situation of a person. In cell therapy, it is used to control the dosage of cells given to the patient. The cell counting segment is anticipated to witness significant growth in the market owing to factors such as a rise in chronic diseases and an increase in the biotech industry and research in cell biology. For instance, as per an article published in February 2022 in Frontiers journal, a high WBC count is positively related to an increased risk of insulin resistance among middle-aged and older people in Taiwan.
Furthermore, an increase in cancer studies involving cell counting is expected to push segment growth over the forecast period. For instance, as per an article published in December 2022 in ASCO Post, a single evaluation of the (circulating tumor cell) count prior to the start of treatment can help patients with (estrogen receptor)-positive/HER2-negative metastatic breast cancer decide between chemotherapy and single-agent endocrine therapy, according to the STIC trial, which is the first to demonstrate the clinical utility of the count as a biomarker in breast cancer care.
Moreover, the major players in the market are concentrating on introducing new technological advancements to improve their market share. For instance, in March 2022, Mindray launched the new BC-700 Series, a revolutionary hematology analyzer series that incorporates complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests.
North America is Anticipated to Hold a Major Share in the Cell Analysis Instruments Market Over the Forecast Period
North America is expected to hold a significant market share over the forecast period due to the increase in incidences of cancer and increasing corporate and government funding in cell-based research. For instance, according to the Canadian Cancer Statistics 2022 Special Report, the number of people living with and after cancer in Canada continued to grow to over 1.5 million people. It was estimated that 233,900 people were likely to be diagnosed with cancer in 2022.
Due to the presence of major companies, their product launches, and the strong R&D in biotechnology, the country is witnessing rapid growth in the market studied. For instance, in September 2022, Becton, Dickinson, and Company launched BD Research Cloud, a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher-quality experiments with faster time to insight for scientists working across a range of disciplines, including immunology, virology, oncology, and infectious disease monitoring.
Furthermore, in December 2022, Asymmetrex planned to develop the first therapeutic stem cell counter based on a new report of validation of rapid stem cell-counting technology. Asymmetrex's newest report on its kinetic stem cell (KSC) counting technology for determining the dosage of therapeutic stem cells was published online in the Journal of Stem Cell Therapy and Transplantation. The company's scientists used commercial preparations of cord blood stem cells and adult blood stem cells to validate its recently reported mathematical equations for the calculation of the dosage of therapeutic stem cells.
